August 2012
-
The Inhalation Asia conference, which will take place in Hong Kong September 13-15 has extended its early bird registration period due to “an issue with the beta version of the website registration module.” The new… Read more . . .
-
Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld… Read more . . .
-
According to Evoke Pharma, the company has reached an agreement with the FDA on design of a PK trial for its Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. The company said that… Read more . . .
-
GSK has voluntarily recalled 593,088 Ventolin inhalers manufactured at its Zebulon, North Carolina facility due to an “Elevated number of units with out of specification results for leak rate.” The lots involved in the level… Read more . . .
-
Device company Nemera has announced that it will develop devices for the delivery of inhaled nanoparticles for the treatment of cardiovascular disease as part of the Cupido (Cardio Ultraefficient Nanoparticles For Inhalation Of Drug Products)… Read more . . .
-
Therapix Biosciences has signed a licensing agreement with Yissum Research Development Company for nasal drug delivery technology that it plans to use for intranasal delivery of cannabinoids, the company said. Yissum Research Development Company is… Read more . . .
-
Sunovion has launched the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD in the United States, the company announced. Sunovion acquired the US rights to the Utibron, Seebri, and Arcapta Neohalers from Novartis in… Read more . . .
-
Verona Pharma has announced a clinical development services agreement with QuintilesIMS for Verona’s RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. The company also said that it is planning… Read more . . .
-
Judge Richard G. Andrews of the US District Court, District of Delaware, has found that Lannett has infringed on the US patents 6,750,237 and 7,220,767 related to Zomig zolmitriptan nasal spray, Impax Laboratories has announced.… Read more . . .
-
Capsugel has added a new Harro Hӧfliger Modu-C MS encapsulation unit with a capacity of over 72,000 capsules per hour for late-stage clinical trial and commercial production of dry powder inhaler formulations, the company said.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland